GYRE

Business Context and Reporting Period

Company: Targacept, Inc. (Note: Input metadata listed "Gyre Therapeutics," but the filing text identifies the registrant as Targacept, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2009
Business Overview: Targacept is a biopharmaceutical company developing novel NNR Therapeutics (neuronal nicotinic receptor modulators) for central nervous system disorders. The company has no internal sales force and relies on strategic alliances for commercialization. Its primary approved product, Inversine (for hypertension), was discontinued effective September 30, 2009.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net operating revenues increased by $5.0 million (25%) primarily due to an $8.8 million increase in milestone and license fee revenue. This was driven by a $10.0 million milestone payment from AstraZeneca for the AZD3480 ADHD trial and recognition of deferred revenue from the new TC-5214 agreement.
• License Fee Expense: A new line item for "License fees and royalties" appeared in 2009 totaling $16.4 million. This was triggered by the receipt of a $200 million upfront payment from AstraZeneca in January 2010 (recorded as a receivable in 2009), which required a $16.0 million payment to the University of South Florida Research Foundation (USFRF).
• Discontinuation of Inversine: The company discontinued its only approved product, Inversine, in September 2009. Product sales revenue declined to $0.5 million from $0.7 million in 2008.
• Collaboration Revenue Decline: Collaboration research and development revenue decreased by $3.7 million as the preclinical research collaboration with AstraZeneca neared its expiration in January 2010.
• Liquidity Improvement: Cash and short-term investments increased by $22.7 million, bolstered by a $44.4 million net proceeds from a public stock offering in October 2009 and the $200 million receivable from AstraZeneca.

Guidance, Outlook, and Risks

• Strategic Alliances:
  • AstraZeneca (TC-5214): Entered a new agreement in December 2009 for the global development of TC-5214 for major depressive disorder. Received a $200 million upfront payment in January 2010. Eligible for up to $1.04 billion in additional milestones and royalties.
  • AstraZeneca (Cognitive Disorders): Continued collaboration on AZD3480 (ADHD) and AZD1446 (Alzheimer's/ADHD). AZD3480 met primary endpoints in a Phase 2 ADHD trial.
  • GlaxoSmithKline (GSK): Strategic alliance covers pain, smoking cessation, addiction, obesity, and Parkinson's. In February 2010, GSK announced plans to cease discovery research in selected neuroscience areas, specifically including pain. Discussions are ongoing, but the company anticipates multiple therapeutic focus areas may be discontinued.
• Outlook: Management expects to fund operations through the end of 2013 based on existing capital resources, excluding potential future milestone payments. The company expects operating losses to continue as it advances clinical programs.
• Risks:
  • Collaborator Dependence: Success depends heavily on AstraZeneca and GSK. GSK's strategic shift poses a risk to future milestone revenue from the alliance.
  • Clinical Trial Uncertainty: Favorable Phase 2 results for TC-5214 and AZD3480 may not be replicated in larger Phase 3 trials.
  • Regulatory: TC-5214 must submit an NDA by October 1, 2012, to qualify for five-year marketing exclusivity as a new chemical entity; otherwise, it may be limited to three years.

Investor Verification Checklist

• TC-5214 Phase 3 Timeline: Verify the initiation and progress of Phase 3 trials for TC-5214 to ensure the October 2012 NDA submission deadline is met for exclusivity.
• GSK Alliance Status: Monitor the outcome of discussions regarding GSK's exit from neuroscience research to determine the impact on future milestone payments and the pain therapeutic focus area.
• AZD3480 Development: Confirm AstraZeneca's commitment to advancing AZD3480 into Phase 2b trials for ADHD and the decision-making process regarding Alzheimer's disease development.
• TC-5619 Licensing: Track the completion of the Phase 2 proof-of-concept trial for TC-5619 to determine if AstraZeneca will exercise its option to license the compound (triggering a $40 million payment).
• Cash Burn Rate: Assess the company's cash runway given the obligation to fund 20% of TC-5214 Phase 3 costs and the potential reduction in GSK-related revenue.